Cost‐effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?

Charles L. Bennett, David Matchar, Doug McCrory, David G. McLeod, E. David Crawford, Bruce E. Hillner
  • Cancer, May 1996, Wiley
  • DOI: 10.1002/(sici)1097-0142(19960501)77:9<1854::aid-cncr15>3.3.co;2-0
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr David Bruce Matchar

In partnership with: